Evidence map›Paper›PMID 31522370›Full record

ArticleCEN case reports2020

Regression of renal amyloid deposits by VAD therapy plus autologous stem cell transplantation in a patient with primary AL amyloidosis.

Naoya Toriu, Naoki Sawa, Rikako Hiramatsu, Hiroki Mizuno, Daisuke Ikuma, Akinari Sekine, Noriko Hayami, Keiichi Sumida, Masayuki Yamanouchi, Eiko Hasegawa and 6 more

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in CEN case reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Kidney biopsy guidebook 2020 in Japan.Clinical and experimental nephrology · 2021
    Guideline
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Naoya ToriuNephrology Center, Toranomon Hospital Kajigaya, 1-3-1, Takatsu, Kawasaki, 212-0015, Kanagawa, Japan. ntoriu@kuhp.kyoto-u.ac.jp.ORCID 0000-0002-3712-6331
Naoki SawaNephrology Center, Toranomon Hospital Kajigaya, 1-3-1, Takatsu, Kawasaki, 212-0015, Kanagawa, Japan.
Rikako HiramatsuNephrology Center, Toranomon Hospital Kajigaya, 1-3-1, Takatsu, Kawasaki, 212-0015, Kanagawa, Japan.
Hiroki MizunoNephrology Center, Toranomon Hospital Kajigaya, 1-3-1, Takatsu, Kawasaki, 212-0015, Kanagawa, Japan.
Daisuke IkumaNephrology Center, Toranomon Hospital Kajigaya, 1-3-1, Takatsu, Kawasaki, 212-0015, Kanagawa, Japan.
Akinari SekineNephrology Center, Toranomon Hospital Kajigaya, 1-3-1, Takatsu, Kawasaki, 212-0015, Kanagawa, Japan.
Noriko HayamiNephrology Center, Toranomon Hospital Kajigaya, 1-3-1, Takatsu, Kawasaki, 212-0015, Kanagawa, Japan.
Keiichi SumidaNephrology Center, Toranomon Hospital Kajigaya, 1-3-1, Takatsu, Kawasaki, 212-0015, Kanagawa, Japan.
Masayuki YamanouchiNephrology Center, Toranomon Hospital Kajigaya, 1-3-1, Takatsu, Kawasaki, 212-0015, Kanagawa, Japan.
Eiko HasegawaNephrology Center, Toranomon Hospital Kajigaya, 1-3-1, Takatsu, Kawasaki, 212-0015, Kanagawa, Japan.
Junichi HoshinoNephrology Center, Toranomon Hospital Kajigaya, 1-3-1, Takatsu, Kawasaki, 212-0015, Kanagawa, Japan.
Kenmei TakaichiNephrology Center, Toranomon Hospital Kajigaya, 1-3-1, Takatsu, Kawasaki, 212-0015, Kanagawa, Japan.
Atsushi WakeDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Kenichi OhashiDepartment of Pathology, Toranomon Hospital, Tokyo, Japan.
Takeshi FujiiDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Yoshifumi UbaraNephrology Center, Toranomon Hospital Kajigaya, 1-3-1, Takatsu, Kawasaki, 212-0015, Kanagawa, Japan.
Toranomon Hospital · JPYokohama City University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report a 58-year-old Japanese woman who presented with nephrotic syndrome. Steroid therapy and cyclosporine A administration were initiated, but hematological remission and renal response were not achieved. Renal biopsy revealed amyloid deposits in the mesangial region and the small arteries. Proteomic analysis based on laser microdissection and mass spectrometry showed that the amyloid deposits were composed of the constant region of the lambda light chain. She received vincristine, adriamycin, and dexamethasone therapy followed by high-dose melphalan and autologous stem cell transplantation, resulting in hematological complete remission and renal response with negative urinary Bence-Jones protein and proteinuria. Renal biopsy was performed four times during follow-up, demonstrating that amyloid deposits decreased gradually, while glomeruli showing global sclerosis increased from 3 to 62%. This case suggests that glomerular amyloid deposits can be cleared via tissue remodeling, if stem cells producing amyloid precursors are completely replaced by unrelated cells after stem cell transplantation.

Indexed as

Antibiotics, AntineoplasticAntineoplastic Agents, HormonalAntineoplastic Agents, PhytogenicAsian PeopleCombined Modality TherapyDexamethasoneDoxorubicinFemaleHematopoietic Stem Cell TransplantationHumansImmunoglobulin lambda-ChainsImmunoglobulin Light-chain AmyloidosisKidneyMelphalanMiddle AgedMyeloablative AgonistsAntibiotics, AntineoplasticAntineoplastic Agents, HormonalAntineoplastic Agents, PhytogenicDexamethasoneDoxorubicinImmunoglobulin lambda-ChainsMelphalanMyeloablative AgonistsVincristineadriamycinAL amyloidosisand dexamethasoneAutologous stem cell transplantationHigh-dose melphalanVincristine

Identifiers

PMID31522370
PMCPMC6990336
OpenAlexW2973227897

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.